Related Experiment Video

Updated: Jul 18, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments

Neeltje Steeghs1, Johan W R Nortier, Hans Gelderblom

  • 1Department of Clinical Oncology K1-P, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. n.steeghs@lumc.nl

Annals of Surgical Oncology
|November 15, 2006
PubMed

Insights

Small molecule tyrosine kinase inhibitors (TKIs) offer targeted cancer therapy with fewer side effects than chemotherapy. These drugs stabilize tumor progression and show promise when combined with other treatments for solid tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinases are oncogenes involved in cell proliferation and differentiation.
  • Small molecule tyrosine kinase inhibitors (TKIs) target these pathways in cancer cells.
  • TKIs represent a newer class of anti-cancer drugs compared to traditional chemotherapy.

Purpose of the Study:

  • To provide an update on registered and developing TKIs for cancer treatment.
  • To discuss the future role of TKIs in managing solid tumors.
  • To review specific TKIs including Imatinib, Gefitinib, and Sorafenib.

Main Methods:

  • Review of currently registered and advanced-stage TKIs.
  • Analysis of TKI efficacy in stabilizing tumor progression.
  • Evaluation of synergistic effects with radiotherapy and chemotherapy.

Main Results:

  • TKIs can stabilize tumor progression, potentially leading to a chronic disease state.
  • TKIs exhibit minimal side effects compared to conventional chemotherapy.
  • In vitro studies show synergistic effects when TKIs are combined with radiotherapy and/or chemotherapy.

Conclusions:

  • TKIs are a valuable addition to cancer treatment, offering targeted therapy with improved tolerability.
  • Further research and development are ongoing for TKIs in solid tumor treatment.
  • The combination of TKIs with other modalities holds significant therapeutic potential.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...